Integra Lifesciences Holdings Corp Expected to Post FY2018 Earnings of $2.35 Per Share (IART)
Integra Lifesciences Holdings Corp (NASDAQ:IART) – Equities research analysts at Northcoast Research boosted their FY2018 earnings per share (EPS) estimates for Integra Lifesciences in a report released on Thursday. Northcoast Research analyst D. Keiser now expects that the life sciences company will post earnings per share of $2.35 for the year, up from their previous forecast of $2.32. Northcoast Research also issued estimates for Integra Lifesciences’ Q4 2018 earnings at $0.69 EPS, Q1 2019 earnings at $0.56 EPS, Q2 2019 earnings at $0.63 EPS, Q3 2019 earnings at $0.67 EPS, Q4 2019 earnings at $0.77 EPS and FY2019 earnings at $2.63 EPS.
Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings data on Tuesday, February 27th. The life sciences company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.56 by $0.08. Integra Lifesciences had a net margin of 5.45% and a return on equity of 17.30%. The business had revenue of $368.60 million during the quarter, compared to the consensus estimate of $362.64 million. During the same quarter in the prior year, the firm earned $0.52 EPS. The business’s revenue was up 44.2% on a year-over-year basis.
Integra Lifesciences (NASDAQ IART) opened at $52.70 on Friday. Integra Lifesciences has a 1-year low of $40.51 and a 1-year high of $56.42. The company has a market cap of $4,059.72, a PE ratio of 64.27, a price-to-earnings-growth ratio of 1.62 and a beta of 0.65. The company has a current ratio of 4.49, a quick ratio of 3.39 and a debt-to-equity ratio of 1.26.
A number of institutional investors have recently bought and sold shares of IART. First Trust Advisors LP raised its position in Integra Lifesciences by 216.1% in the 3rd quarter. First Trust Advisors LP now owns 51,084 shares of the life sciences company’s stock worth $2,579,000 after purchasing an additional 34,925 shares during the period. Crossmark Global Holdings Inc. purchased a new stake in Integra Lifesciences in the 3rd quarter worth about $619,000. Stevens Capital Management LP purchased a new stake in Integra Lifesciences in the 3rd quarter worth about $647,000. Stoneridge Investment Partners LLC purchased a new stake in Integra Lifesciences in the 3rd quarter worth about $572,000. Finally, Prudential Financial Inc. raised its position in Integra Lifesciences by 3.3% in the 3rd quarter. Prudential Financial Inc. now owns 105,836 shares of the life sciences company’s stock worth $5,343,000 after purchasing an additional 3,340 shares during the period. 86.39% of the stock is currently owned by institutional investors.
In related news, Director Keith Bradley sold 15,658 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $55.00, for a total value of $861,190.00. Following the sale, the director now directly owns 37,074 shares of the company’s stock, valued at approximately $2,039,070. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 21.50% of the stock is currently owned by company insiders.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.